Newly emerging pharmacologic differences in angiotensin II receptor blockers

American Journal of Hypertension

Volumn 13, Issue 1 II SUPPL., 2000, Pages

  Oparil, Suzanne ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b 1034 Zeigler Research Building ^*  (United States)

Author keywords

Angiotensin II receptor blockers; Candesartan cilexetil; Pharmacokinetics; Pharmacology

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; EPROSARTAN; IRBESARTAN; LOSARTAN; LOSARTAN POTASSIUM; TELMISARTAN; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; COMPETITIVE INHIBITION; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW;

EID: 0033950686     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(99)00250-2     Document Type: Review

References (27)

1. Burnier M, Brunner HR: Angiotensin II receptor antagonists in hypertension. Kidney Intern 1998;54(suppl 68):S107-S111.
2. Awan NA, Mason DT: Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Am Heart J 1996;131:177-185.
3. Ellis ML, Patterson JH: A new class of antihypertensive therapy: angiotensin II receptor antagonists. Pharmacother 1996;16:849-860.
4. Horiuchi M, Akishita M, Dzau VJ: Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-621.
5. 2 receptors. Kidney Intern 1998;67(suppl):S95-S99.
6. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD: Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174. Clin Pharmacol Ther 1995;58:641-649.
7. Hübner R, Högemann AM, Sunzel M, Riddell JG: Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Human Hypertens 1997;11(suppl 2):S19-S25.
8. Nishikawa K, Naka T, Chatani F, Yoshimura Y: Candesartan cilexetil: a review of its preclinical pharmacology. J Human Hypertens 1997;11(suppl 2):S9-S17.
9. Johnston CI, Risvanis J: Preclinical pharmacology of angiotensin II receptor antagonists. Update and outstanding issues. Am J Hypertens 1997;10:306S-310S.
10. Inada Y, Ojima M, Kanagawa R, Misumi Y, Nishikawa K, Naka T: Pharmacological properties of candesartan cilexetil - possible mechanisms of long-acting antihypertensive action. J Human Hypertens 1999;12(suppl 1):S75-S80.
11. Ruddy MC, Kostis JB: Angiotensin II receptor antagonists, in Oparil S, Weber M (eds): Hypertension. Philadelphia, WB Saunders, 1999, chapter 71, 621-636.
12. Waeber B, Brunner HR: A look through the new therapeutic window: irbesartan. J Hypertens 1998;16(suppl 7):S11-S16.
13. Flesch G, Muller P, Lloyd P: Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 1997; 52:115-120.
14. Tenero D, Martin D, Ilson B, Jushchyshyn J, Boike S, Lundberg D, Zariffa N, Boyle D, Jorkasky D: Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. Biopharm Drug Dispos 1998;19:351-356.
15. Goa KL, Wagstaff AJ: Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996;51:820-845.
16. 14C-candesartan cilexetil in healthy volunteers. J Human Hypertens 1997;11(suppl 2):S27-S28.
17. Physicians' Desk Reference, 53rd ed: Valsartan, in Physicians' Desk Reference. Montvale, NJ, Medical Economics, 1999, pp 2013-2014.
18. Riddell JG: Bioavailability of candesartan is uneffected by food in healthy volunteers administered candesartan cilexetil. J Human Hypertens 1997;11(suppl 2):S29-S30.
19. Belz GG, Fuchs B, Malerczyk C, Magin SG, Roll S, Mutschler E: Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Human Hypertens 1997;11(suppl 2):S45-S47.
20. de Zeeuw D, Remuzzi G, Kirch W: Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Human Hypertens 1997;11(suppl 2):S37-S42.
21. 1 receptor antagonists feasible in normotensive volunteers (abst)? 8th European Meeting on Hypertension, Milan, Italy. June 13-16, 1997.
22. Andersson OK, Neldam S: A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J Human Hypertens 1997;11(suppl 2):S63-64.
23. Andersson OK, Neldam S: The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998;7:53-59.
24. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E (for the Irbesartan/Losartan Study Investigators): Comparative efficacy of two angiotensin receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998;11:445-453.
25. Oparil S, Guthrie R, Lewin AJ, Marbury T, Reilly K, Triscari J, Witcher JA: An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Clin Ther 1998;20: 398-409.
26. Reif M, White WB, Pagan TC, Oparil S, Flanagan TL, Edwards DT, Cushing DJ, Michelson EL: Effects of candesartan cilexetil in patients with systemic hypertension. Am J Cardiol 1998;82:961-965.
27. Nakashima M, Uematsu T, Kosuge K, Kanamaru M: Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992;42:333-335.